A Comparison of the Cyclic Variation in Serum Levels of CA125 Across the Menstrual Cycle Using Two Commercial Assays

Biological Research for Nursing

Volumn 14, Issue 3, 2012, Pages 250-256

  McLemore, Monica R ^a   Aouizerat, Bradley E ^a   Lee, Kathryn A ^a   Chen, Lee may ^b   Cooper, Bruce ^a   Tozzi, Michael ^a   Miaskowski, Christine ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CA125; menstrual cycle; ovarian cancer screening; premenopausal women

Indexed keywords

CA 125 ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; BLOOD; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MENSTRUAL CYCLE; METHODOLOGY; REFERENCE VALUE;

ADOLESCENT; ADULT; CA-125 ANTIGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MENSTRUAL CYCLE; REFERENCE VALUES; YOUNG ADULT;

EID: 84862290603     PISSN: 10998004     EISSN: 15524175     Source Type: Journal    
DOI: 10.1177/1099800411412766     Document Type: Article

References (40)

1. Andersen M. R.,Goff B. A.,Lowe K. A.,Scholler N.,Bergan L.,Drescher C. W.,Urban N.Combining a symptoms index with CA125 to improve detection of ovarian cancer.Cancer. 2008;113:484-489.
2. Bast R. C.,Badgwell D.,Lu Z.,Marquez R.,Rosen D.,Liu J.,Lu K.New tumor markers: CA125 and beyond.International Journal of Gynecologic Cancer. 2005;3:274-281.
3. Bon G. G.,Kenemans P.,Dekker J. J.,Hompes P. G.,Verstraeten R. A.,van Kamp G. J.,Schoemaker J.Fluctuations in CA 125 and CA 15-3 serum concentrations during spontaneous ovulatory cycles.Human Reproduction. 1999;14:566-570.
4. Bon G. G.,Kenemans P.,Verstraeten R. A.,van Kamp G. J.,Hilgers J.Serum tumor marker immunoassays in gynecologic oncology: Establishment of reference values.American Journal of Obstetrics and Gynecology. 1995;174:107-114.
5. Bonfrer J. M. G.,Baan A. W.,Jansen E.,Lentfer D.,Kenemans P.The technical evaluation of the three second generation CA125 assays.European Journal of Clinical Chemistry and Clinical Biochemistry. 1994;32:201-207.
6. Bonfrer J. M. G.,Korse C. M.,Verstraeten R. A.,van Kamp G. J.,Hart G. A.,Kenemans P.Clinical evaluation of the Byk LIA-mat CA125 II assay: Discussion of a reference value.Clinical Chemistry. 1997;43:491-497.
7. Buys S. S.,Partridge E.,Green M. H.,Prorok P. C.,Reding D.,Riley T. L.Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trial.American Journal of Obstetrics and Gynecology. 2005;193:1630-1639.
8. Clement M.,Bischof P.,Gruffat C.,Ricolleau G.,Auvray E.,Quillien V.,Ferdeghini M.Clinical validation of the new ELSA-CA 125 II assay: Report of a European multicentre evaluation.International Journal of Cancer. 1995;60:199-203.
9. Crump C.,McIntosh M. W.,Urban N.,Anderson G.,Karlan B. Y.Ovarian cancer tumor marker behavior in asymptomatic healthy women: Implications for screening.Cancer Epidemiology, Biomarkers, and Prevention. 2000;9:1107-1111.
10. Davelaar E. M.,Schutter E. M.,von Mensdorff-Pouilly S.,van Kamp G. J.,Verstraeten R. A.,Kenemans P.Clinical and technical evaluation of the ACS: OV serum assay and comparison with three other CA125-detecting assays.Annals of Clinical Biochemistry. 2003;40:663-673.
11. Davelaar E. M.,van Kamp G. J.,Verstraeten R. A.,Kenemans P.Comparison of seven immunoassays for the quantification of CA 125 antigen in serum.Clinical Chemistry. 1998;44:1417-1422.
12. Duffy M. J.,Bonfrer J. M.,Kulpa J.,Rustin G. J.,Soletormos G.,Torre G. C.,Zwirner M.CA125 in ovarian cancer: European group on tumor markers guidelines for clinical use.International Journal of Gynecologic Cancer. 2005;15:679-691.
13. Fehring R. J.,Schneider M.,Raviele K.Variability in the phases of the menstrual cycle.Journal of Obstetrics, Gynecology, and Neonatal Nursing. 2006;35:376-384.
14. Fisken J.,Leonard R. C.,Roulston J. E.Immunoassay of CA125 in ovarian cancer: A comparison of three assays for use in diagnosis and monitoring.Disease Markers. 1989;7:61-67.
15. Frasier I. S.,Jansen R. P. S.,Lobo R. A.,Whitehead M. I.Estrogens and progesterones in clinical practice. 1998). Estrogens and progesterones in clinical practice3rd ed.).Philadelphia, PA: Churchill Livingston/Harcourt Brace; 1998:.
16. Hornstein M. D.,Goodman H. M.,Thomas P. P.,Knapp R. C.,Harlow B. L.Use of a second-generation CA125 assay in gynecologic patients.Gynecologic and Obstetric Investigation. 1996;42:196-200.
17. Jacobs I.,Bast R. C.The CA125 tumour-associated antigen: A review of the literature.Human Reproduction. 1989;4:1-12.
18. John E. M.,Whittemore A. S.,Harris R.,Intyre J.Characteristics relating to ovarian cancer risk: Collaborative analysis of seven US case-control studies: Epithelial ovarian cancer in black women.Journal of the National Cancer Institute. 1993;85:142-146.
19. Johnson C. C.,Kessel B.,Riley T. L.,Ragard L. R.,Williams C. R.,Xu J-L,.The epidemiology of CA125 in women without evidence of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.Gynecologic Oncology. 2008;110:383-389.
20. Kafali H.,Artunc H.,Erdem M.Evaluation of factors that may be responsible for cyclic changes of CA125 levels during menstrual cycle.Archives of Gynecology and Obstetrics. 2007;275:175-177.
21. Kan Y. Y.,Yeh S. H.,Ng H. T.,Lou C. M.Effect of menstruation on serum CA125 levels.Asia Oceania Journal of Obstetrics and Gynaecology. 1992;18:339-343.
22. Kenemans P.,van Kamp G. J.,Oehr P.,Verstraeten R. A.Heterologous double-determinant immunoradiometeric assay CA125 II: Reliable second-generation immunoassay for determining CA125 in serum.Clinical Chemistry. 1993;39:2509-2513.
23. Kenemans P.,Verstraeten A. A.,van Kamp G.,Mensdorff-Pouilly S.The second generation CA125 assays.Annals of Medicine. 1995;27:107-113.
24. Kobayashi H.,Tamura M.,Satoh T.,Terao T.Clinical evaluation of new cancer-associated antigen CA125 II in epithelial ovarian cancers: Comparison with CA125.Clinical Biochemistry. 1993;26:213-219.
25. Lee K.,Shaver J. F.,Giblin E. C.,Woods N. F.Sleep patterns related to menstrual cycle phase and premenstrual affective symptoms.Sleep. 1990;13:403-409.
26. Lehtovirta P.,Apter D.,Stenman U-H.Serum CA125 levels during the menstrual cycle.British Journal of Obstetrics and Gynecology. 1990;97:930-933.
27. Martin M.,Blockx P.Comparison of one first and three second generation methods for the determination of CA 125.Anticancer Research. 1997;17:3171-3175.
28. McLemore M. R.,Miaskowski C.,Aouizerat B. E.,Chen L. -M.,Dodd M. J.Epidemiological and genetic risk factors associated with ovarian cancer.Cancer Nursing. 2009;32:281-288.
29. Meden H.,Fattahi-Meibodi A.CA 125 in benign gynecological conditions.International Journal of Biological Markers. 1998;13:231-237.
30. National Cancer Institute (NCI). (n.d.). Ovarian cancer research results from the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: Fact sheet. Retrieved August 12, 2008, fromhttp://previewqa.cancer.gov/cancertopics/factsheet/detection/plco-ovarian.
31. Nguyen H. N.,Jacobson A.,Patino-Paul R.New reference levels for CA125 in pre-and postmenopausal women.Primary Care Update for OB/GYNs. 1998;5:157.
32. Nustad K.,Onsrud M.,Jansson B.,Warren D.CA125-epitopes and molecular size.International Journal of Biological Markers. 1998;13:196-199.
33. Pauler D. K.,Menon U.,McIntosh M.,Symecko H. L.,Skates S. J.,Jacobs I. J.Factors influencing serum CA125II levels in healthy postmenopausal women.Cancer Epidemiology, Biomarkers, and Prevention. 2001;10:489-493.
34. Rodriguez C.,Calle E. E.,Fakhrabadi-Shokoohi D.,Jacobs E. J.,Thun M. J.Body mass index, height, and the risk of ovarian cancer mortality in a prospective cohort of postmenopausal women.Cancer Epidemiology, Biomarkers, and Prevention. 2002;11:822-828.
35. Rubin S. C.,Sutton G. P.Ovarian cancer. 2004). Ovarian cancer2nd ed.).Philadelphia, PA: Lippincott, Williams & Wilkins; 2004:.
36. Runnebaum I. B.,Stickeler E.Epidemiological and molecular aspects of ovarian cancer risk.Journal of Cancer Research and Clinical Oncology. 2001;127:73-79.
37. Speroff L.,Fritz M. A.Clinical gynecologic endocrinology and infertility. 2005). Clinical gynecologic endocrinology and infertility7nd ed.).Philadelphia, PA: Lippincott, Williams & Wilkins; 2005:.
38. van Kamp G. J.,Verststraeten A. A.,Kenemans P.Discordant serum CA125 values in commercial immunoassays.European Journal of Obstetrics & Gynecology and Reproductive Biology. 1993;49:99-103.
39. Yan G.,Ju H.,Liang Z.,Zhang T.Technical and clinical comparison of two fully automated methods for the immunoassay of CA125 in serum.Journal of Immunological Methods. 1999;225:1-8.
40. Yedema K. A.,Thomas C. M. G.,Segers M. F. G.,Doesburg W. H.,Kenemans P.Comparison of five immunoassay procedures for the ovarian carcinoma-associated antigenic determinant CA125 in serum.European Journal of Obstetrics & Gynecology and Reproductive Biology. 1992;47:245-251.